Last updated: November 11, 2026
ecutive summary: Amyvid (florbetapir F 18 injection) is a niche diagnostic radiopharmaceutical used with PET imaging to estimate beta-amyloid neuritic plaque density in adults being evaluated for Alzheimer’s disease and other cognitive impairment. Eli Lilly owns and markets the product through Avid Radiopharmaceuticals. Its commercial trajectory has been driven by PET capacity, reimbursement, specialist adoption and the expansion of disease-modifying Alzheimer’s therapies, rather than by broad prescription volume. Lilly does not disclose Amyvid revenue separately, indicating that the product is immaterial to consolidated sales. The main risks are competition from other amyloid PET agents, blood-based biomarkers, radiotracer production constraints and pressure on diagnostic demand as clinicians adopt lower-cost testing.
Amyvid Florbetapir Market Dynamics, Financial Trajectory, Patent Status and Competitive Outlook
What is Amyvid and how does it work?
Amyvid is the brand name for florbetapir F 18 injection, a radioactive diagnostic agent used with positron emission tomography. It binds to beta-amyloid plaques in the brain. A positive scan indicates moderate to frequent amyloid neuritic plaque density, while a negative scan is inconsistent with those levels at the time of imaging.
Amyvid does not diagnose Alzheimer’s disease by itself. The FDA label states that the result must be interpreted with other clinical information and that a positive scan does not establish a diagnosis of Alzheimer’s disease or another cognitive disorder. The product also does not measure disease progression or predict future cognitive decline. [1]
| Attribute |
Amyvid |
| Active ingredient |
Florbetapir F 18 |
| Drug class |
Amyloid PET radiopharmaceutical |
| FDA application |
NDA 202008 |
| FDA approval |
April 6, 2012 |
| Administration |
Intravenous injection |
| Imaging modality |
PET |
| Primary use |
Estimation of beta-amyloid neuritic plaque density |
| Physical half-life |
Approximately 110 minutes |
| Commercial owner |
Eli Lilly and Company through Avid Radiopharmaceuticals |
| Prescription model |
Radiopharmaceutical dose administered at imaging centers |
| Direct substitutes |
Neuraceq, Vizamyl and emerging amyloid PET or blood-based biomarkers |
The product’s short half-life creates a different commercial model from conventional pharmaceuticals. Amyvid is produced, transported and administered within a tightly controlled time window. Revenue depends on radiopharmacy logistics, PET scanner availability and reimbursement per completed scan.
When did Amyvid receive FDA approval?
The FDA approved Amyvid in 2012 under the agency’s framework for amyloid PET imaging agents. At approval, the FDA required further postmarketing work to improve reader training and address interpretation variability. Lilly’s Avid Radiopharmaceuticals developed florbetapir before Lilly acquired the company in 2010 for approximately $300 million in upfront consideration, plus potential milestone payments. [2]
The approval created the first FDA-authorized commercial amyloid PET agent in the United States. Amyvid was followed by:
| Product |
Active ingredient |
FDA approval |
| Amyvid |
Florbetapir F 18 |
2012 |
| Vizamyl |
Flutemetamol F 18 |
2013 |
| Neuraceq |
Florbetaben F 18 |
2014 |
The three products have similar diagnostic positioning but differ in tracer chemistry, image interpretation requirements, distribution networks and commercial contracting.
What drives Amyvid demand?
Amyvid demand is tied to the number of patients who receive specialist cognitive evaluation and are considered eligible for amyloid confirmation. The principal demand drivers are:
- Growth in Alzheimer’s disease evaluation.
- Increased use of disease-modifying therapies that require amyloid confirmation.
- Expansion of PET imaging capacity.
- Medicare and commercial reimbursement.
- Availability of radiopharmacy production and delivery.
- Physician confidence in amyloid PET interpretation.
The approval of Leqembi (lecanemab) and Kisunla (donanemab) increased the clinical value of amyloid confirmation. Both therapies target patients with confirmed amyloid pathology, creating a diagnostic pathway in which Amyvid can be used before treatment initiation or when other diagnostic evidence is insufficient. [3][4]
This opportunity is offset by the emergence of blood-based biomarkers. Plasma beta-amyloid and phosphorylated tau tests are less expensive, easier to distribute and do not require a PET scanner. If validated and broadly reimbursed, blood tests could be used as a front-line screen, reserving Amyvid for indeterminate cases, treatment qualification or clinical trials.
How has the Amyvid financial trajectory developed?
Amyvid’s revenue has not been reported as a standalone line item by Eli Lilly. Lilly’s annual reports group smaller products within broader revenue categories and do not provide a product-specific Amyvid sales figure. The absence of separately reported revenue indicates that Amyvid is not material to Lilly’s consolidated financial statements. [5]
The commercial trajectory can be divided into four periods:
| Period |
Market condition |
Financial implication |
| 2012-2014 |
First-mover launch, limited reimbursement and low physician familiarity |
Slow initial adoption and high education costs |
| 2015-2019 |
Greater clinical use but constrained by PET access and coverage rules |
Gradual volume growth without mass-market scale |
| 2020-2022 |
Greater interest in biomarker-confirmed Alzheimer’s diagnosis |
Improved strategic value, but pandemic and reimbursement constraints affected utilization |
| 2023 onward |
Expansion of anti-amyloid treatment pathways and competition from blood tests |
Higher potential scan demand with greater substitution risk |
Amyvid is economically different from a chronic branded medicine. The product is sold per administered dose, and revenue depends on completed scans rather than refills. A radiopharmaceutical may have attractive per-dose pricing, but wastage, distribution and production costs can reduce contribution margins. The product also requires local or regional supply arrangements because the radioactive isotope decays rapidly.
Lilly’s financial exposure is therefore modest relative to its major therapeutic franchises. Amyvid has strategic importance because it supports Alzheimer’s diagnostic infrastructure and may help identify patients for Lilly’s Alzheimer’s portfolio, but it is not a major earnings driver on a standalone basis.
What is the reimbursement status of Amyvid?
The Centers for Medicare & Medicaid Services initially restricted national coverage of amyloid PET under a coverage-with-evidence-development framework. CMS later revised its position and removed the prior national limitation, allowing coverage decisions to align more closely with FDA-approved use and Medicare administrative policies. [6]
Coverage remains dependent on the clinical setting, beneficiary eligibility, local contractor policy and documentation. Commercial insurers may impose prior authorization or require evidence that the scan will affect patient management.
Amyvid’s reimbursement economics depend on several components:
- The radiopharmaceutical payment.
- The technical component for PET imaging.
- The professional interpretation fee.
- Hospital or imaging-center overhead.
- Radiopharmacy distribution costs.
A scan can generate more total healthcare revenue than the drug component alone. Lilly captures only the Amyvid dose, while imaging centers, radiopharmacies and physicians receive the remaining payments.
What patents protect Amyvid?
Amyvid’s original patent value was based on florbetapir, amyloid-binding compounds, radiolabeling methods, imaging methods and use of PET to estimate amyloid plaque burden. Patent protection is distinct from FDA regulatory exclusivity and from reimbursement status.
The key commercial point is that Amyvid launched in 2012 and is now beyond the period when original U.S. composition and use patents would normally provide a durable barrier. Any remaining enforceable rights would need to be assessed patent-by-patent, including terminal disclaimers, patent-term adjustment, continuations and jurisdiction-specific prosecution history.
The FDA Orange Book and USPTO records are the controlling sources for current listed patents and expiry dates. Amyvid does not have the patent profile of a modern biologic or long-duration specialty therapy. Its competitive protection is more dependent on:
- FDA approval of a specific florbetapir product.
- Radiopharmaceutical manufacturing controls.
- Distribution networks.
- PET-site contracts.
- Reader training and clinical familiarity.
- Reimbursement and operational execution.
Are there formulation patents for Amyvid?
Amyvid’s formulation and manufacturing rights may cover radiolabeling, drug substance preparation, quality control, sterile production and administration. These rights can be commercially relevant even when broad molecule patents have expired or become less important.
Formulation claims are less likely to block all competing amyloid PET products because competitors use different active ingredients. They can, however, limit direct copies of the same florbetapir formulation or manufacturing process.
Are there Paragraph IV challenges to Amyvid?
Publicly visible commercial activity has not established a major Paragraph IV litigation campaign against Amyvid comparable to litigation involving high-revenue oral medicines or biologics. A generic applicant would face several practical barriers:
- Demand is concentrated in specialized imaging centers.
- Product manufacture requires radioactive isotope handling.
- The short half-life complicates national distribution.
- Approval requires validated PET image interpretation and product-specific clinical evidence.
- Market size may not justify substantial litigation and launch costs.
- Reimbursement and site capacity constrain volume.
A 505(j) generic could still enter if it demonstrates pharmaceutical equivalence and bioequivalence or otherwise satisfies FDA requirements. The regulatory pathway for a radiopharmaceutical is more operationally complex than that of a conventional tablet or capsule.
Which companies compete with Amyvid?
Amyvid competes directly with the other FDA-approved amyloid PET agents:
| Product |
Company |
Differentiation |
| Amyvid |
Eli Lilly/Avid |
First U.S.-approved amyloid PET agent; florbetapir platform |
| Vizamyl |
GE HealthCare |
Flutemetamol F 18; established imaging and radiopharmacy presence |
| Neuraceq |
Life Molecular Imaging |
Florbetaben F 18; competing amyloid PET tracer |
The competitive landscape also includes diagnostic alternatives that are not direct drug substitutes.
How do blood biomarkers affect Amyvid?
Blood-based biomarkers are the most important long-term competitive threat. They offer lower cost, simpler logistics and wider access than PET imaging. Their near-term limitations include variable assay performance, differences among platforms, laboratory requirements and evolving reimbursement.
Amyvid is more likely to retain a role in confirmatory testing, clinical trials, complex cases and treatment eligibility where high diagnostic confidence is required. Routine first-line screening is the segment most exposed to blood tests.
How does Amyvid compare with Vizamyl and Neuraceq?
The products compete on image quality, reader confidence, site economics, availability and payer acceptance. None has a permanent monopoly over amyloid PET imaging. Because all are used with PET, infrastructure and radiopharmacy access can matter as much as molecular differentiation.
Amyvid’s first-mover status supports physician familiarity, but it does not eliminate substitution. A PET center can select among agents based on supply reliability, contracting, training and local economics.
What manufacturing and intellectual-property barriers affect Amyvid?
Manufacturing is a meaningful barrier even if patent protection weakens. Amyvid requires:
- Production of fluorine-18.
- Radiochemical synthesis.
- Sterile injectable manufacturing.
- Quality-control release procedures.
- Time-sensitive transport.
- Specialized handling and waste management.
- Trained nuclear medicine personnel.
The 110-minute half-life limits inventory flexibility. A production interruption can cause missed scans, while excess production can create waste. Regional manufacturing capacity and delivery radius are therefore important competitive assets.
Intellectual property around production methods can add protection, but manufacturing know-how, regulatory compliance and supply reliability may be more durable commercial advantages than a single patent.
What litigation and settlement agreements affect Amyvid?
No major, publicly established patent settlement has defined Amyvid’s U.S. market in the manner seen with leading chronic medicines. The main legal exposure is more likely to arise from patent scope, manufacturing rights, product liability, labeling, reimbursement disputes and contracting than from a large generic-entry settlement.
The absence of a major settlement does not mean that all patent risk is eliminated. It means that no publicly disclosed litigation event has become a primary determinant of Amyvid’s market access or forecasted revenue.
What is the generic launch risk for Amyvid?
Near-term generic risk is moderate in regulatory terms but limited in commercial impact. An approved competing florbetapir product could pressure dose pricing, but total market expansion from Alzheimer’s treatment may offset some price erosion.
A realistic launch scenario would likely involve:
- Entry by a specialized radiopharmaceutical company.
- Initial availability in selected metropolitan PET markets.
- Price competition at high-volume imaging sites.
- Limited national penetration because of isotope logistics.
- Greater substitution in routine diagnostic use than in specialized treatment qualification.
The most disruptive competitor is not necessarily a generic injection. A validated blood test with broad payer coverage could reduce the number of PET scans required per patient.
What is the FDA and Orange Book status of Amyvid?
Amyvid remains an FDA-approved product for its labeled indication. FDA approval does not guarantee universal reimbursement or clinical use. The product’s commercial status depends on continued manufacturing, distribution and healthcare-provider demand.
The FDA Orange Book is the relevant source for any current listed patents, exclusivity codes and approved product information. Amyvid’s principal regulatory exclusivity period has long passed. The product’s current economic position is therefore based on approved labeling, operational execution and clinical utility rather than new-drug exclusivity.
What revenue exposure does Amyvid create for Eli Lilly?
Amyvid creates limited direct revenue exposure for Lilly. Lilly does not report Amyvid as a separately material product, so investors cannot derive annual Amyvid sales, gross margin or geographic revenue from public company reporting.
Its indirect strategic value is greater. Amyvid can support the diagnostic workup required for patients being considered for Lilly’s Alzheimer’s treatment franchise. That creates a portfolio linkage, although patients may use Vizamyl, Neuraceq, cerebrospinal-fluid testing or blood biomarkers instead.
The principal financial variables are:
| Variable |
Effect on Amyvid |
| Alzheimer’s diagnosis volume |
Increases addressable demand |
| Anti-amyloid treatment adoption |
Increases need for amyloid confirmation |
| PET scanner availability |
Limits utilization |
| Medicare coverage |
Determines access for older patients |
| Blood biomarker adoption |
Reduces routine PET demand |
| Radiopharmacy capacity |
Determines reliable supply |
| Generic or tracer competition |
Pressures dose pricing |
| Lilly Alzheimer’s portfolio growth |
Increases indirect strategic value |
How strong is the Amyvid patent estate?
Amyvid has a weaker long-term exclusivity profile than a recently launched biologic or specialty small molecule. Original patent protection is aged, regulatory exclusivity has expired, and direct competition from Vizamyl and Neuraceq has existed for years.
The estate remains commercially relevant where claims cover specific formulations, manufacturing methods or imaging uses. Its overall strength is best characterized as operationally defensible rather than strongly patent-blocked. The strongest barriers are product quality, isotope logistics, site relationships and clinical workflow integration.
Key Takeaways
- Amyvid is florbetapir F 18, an FDA-approved amyloid PET radiopharmaceutical.
- It was approved in 2012 and is owned and marketed by Eli Lilly through Avid Radiopharmaceuticals.
- Lilly does not disclose Amyvid revenue separately, indicating limited direct financial materiality.
- Demand increased with the development of anti-amyloid Alzheimer’s therapies that require confirmed amyloid pathology.
- PET capacity, radiopharmacy logistics and reimbursement determine commercial performance.
- Vizamyl and Neuraceq are direct branded competitors.
- Blood-based biomarkers are the largest long-term threat to routine Amyvid utilization.
- Original regulatory exclusivity has expired, and the product has a mature patent profile.
- Manufacturing complexity and short radioactive half-life reduce the likelihood of rapid nationwide generic substitution.
- Amyvid’s indirect value to Lilly may exceed its direct product revenue because it supports Alzheimer’s treatment diagnosis.
FAQs About Amyvid Market Access and Commercial Outlook
Is Amyvid still available in the United States?
Amyvid remains an FDA-approved amyloid PET radiopharmaceutical. Availability depends on regional radiopharmacy production, PET-site contracts and ordering logistics.
Does Amyvid treat Alzheimer’s disease?
No. Amyvid is a diagnostic imaging agent. It estimates amyloid plaque density and does not treat Alzheimer’s disease or slow cognitive decline.
Can Amyvid be used to qualify patients for Leqembi or Kisunla?
Amyloid PET can provide evidence of amyloid pathology relevant to treatment evaluation. Final eligibility depends on the specific FDA label, clinical assessment, imaging findings and applicable treatment protocols.
Is Amyvid more expensive than a blood test?
Amyvid generally involves the cost of the radiotracer, PET imaging, professional interpretation and facility services. Blood-based tests can have lower total testing costs, although reimbursement and clinical validation vary by assay.
Will generic Amyvid eliminate Lilly’s diagnostic revenue?
A generic could pressure florbetapir pricing, but rapid isotope decay, specialized manufacturing and limited PET-site demand make market penetration more complex than for a conventional oral generic.
References
- U.S. Food and Drug Administration. (2012). Amyvid (florbetapir F 18 injection) prescribing information.
- Eli Lilly and Company. (2010, October 19). Lilly to acquire Avid Radiopharmaceuticals.
- U.S. Food and Drug Administration. (2023). Leqembi (lecanemab-irmb) prescribing information.
- U.S. Food and Drug Administration. (2024). Kisunla (donanemab-azbt) prescribing information.
- Eli Lilly and Company. (2024). 2023 annual report.
- Centers for Medicare & Medicaid Services. (2023). Medicare coverage of beta amyloid PET in dementia and neurodegenerative disease.
